Quick answer: Omega-3 fatty acids at therapeutic doses (2–4 g EPA+DHA/day) reduce cardiovascular events by 25% (REDUCE-IT trial, n=8,179), lower triglycerides by 30–50%, and reduce inflammatory markers including hsCRP, IL-6, and TNF-α—making anti-inflammatory nutrition one of the highest-yield interventions in functional medicine with effects measurable within 8–12 weeks.
The Inflammatory Basis of Chronic Disease
Chronic low-grade inflammation—distinct from the acute, protective inflammation of injury—drives the pathophysiology of cardiovascular disease, type 2 diabetes, neurodegenerative conditions, autoimmune disorders, and certain cancers. Unlike acute inflammation, which resolves within days, chronic inflammation persists for years or decades, creating sustained oxidative stress, endothelial dysfunction, insulin resistance, and tissue remodeling that underlies the most prevalent and costly diseases of modern civilization.
The inflammatory cascade centers on nuclear factor kappa B (NF-κB), a transcription factor that upregulates over 200 pro-inflammatory genes when activated by oxidized LDL, advanced glycation end-products (AGEs), lipopolysaccharide (LPS) from gut dysbiosis, visceral adiposity, and environmental toxins. NF-κB activation drives expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and inflammatory cytokines including IL-1β, IL-6, TNF-α, and IL-18—creating a self-amplifying cycle that, once established, becomes self-sustaining independent of the original trigger.
The functional medicine approach to inflammation begins with the recognition that dietary patterns, not individual nutrients in isolation, are the primary modulators of systemic inflammation. The Western diet—characterized by high omega-6 polyunsaturated fatty acids, refined carbohydrates, ultra-processed foods, and minimal omega-3 fatty acids and phytonutrients—creates a pro-inflammatory milieu at the cellular membrane level. Mediterranean and ancestral dietary patterns, by contrast, provide a dense supply of anti-inflammatory precursors that resolve rather than merely suppress inflammation through specialized pro-resolving mediators (SPMs).
Omega-3 Fatty Acids: EPA, DHA, and the Resolution Cascade
The omega-3 fatty acids eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3) are not merely anti-inflammatory in the traditional sense—they are pro-resolving, meaning they actively terminate inflammation rather than blocking its initiation. EPA and DHA serve as precursors to specialized pro-resolving mediators: resolvins (Rv series), protectins/neuroprotectins (PD/NPD series), and maresins—bioactive lipids that promote neutrophil apoptosis, macrophage phagocytosis of cellular debris, and tissue repair without the immune suppression associated with corticosteroids or NSAIDs.
The omega-6:omega-3 ratio in ancestral diets approximated 1:1 to 4:1. The modern Western diet achieves ratios of 15:1 to 25:1, reflecting dramatic increases in linoleic acid (LA, C18:2n-6) from refined vegetable oils and near-elimination of EPA/DHA from marine sources. Arachidonic acid (AA, C20:4n-6), derived from LA via the FADS1 enzyme, competes with EPA for COX and LOX enzymes—when AA predominates, the enzymatic products are highly inflammatory 2-series prostaglandins (PGE2), 2-series thromboxanes (TXA2), and 4-series leukotrienes (LTB4). EPA-derived products are the 3-series prostaglandins and 5-series leukotrienes—biologically much less inflammatory. DHA-derived products (docosatrienes, protectins) are actively anti-inflammatory.
The REDUCE-IT trial (Bhatt 2019, NEJM, n=8,179) demonstrated that icosapentaenoic acid (IPE/EPA ethyl ester, 4 g/day) reduced the composite of cardiovascular death, MI, stroke, coronary revascularization, and unstable angina by 25% (HR 0.75, 95% CI 0.68-0.83, p<0.001) in patients with elevated triglycerides (≥150 mg/dL) on statin therapy. Cardiovascular death specifically was reduced by 20%. The NNT to prevent one event was 21 over 4.9 years—comparable to high-intensity statins. The benefit appeared beyond TG lowering, implicating membrane incorporation, plaque stabilization, and reduced platelet aggregation as additional mechanisms.
The STRENGTH trial (Nicholls 2020, JAMA, n=13,078) using omega-3 carboxylic acids (EPA+DHA combination) found no cardiovascular benefit—the divergence from REDUCE-IT has been attributed to EPA-DHA competition (DHA may partially attenuate EPA’s benefits), the corn oil comparator used in STRENGTH potentially being pro-inflammatory, and the difference in EPA plasma levels achieved. This controversy highlights the importance of pure EPA preparation and achieving adequate plasma levels (EPA:AA ratio target above 0.8, achievable with 2-4 g/day EPA).
Clinical Evidence for Triglyceride and Cardiovascular Risk Reduction
Omega-3 fatty acids reduce fasting triglycerides dose-dependently: 1 g/day reduces TG by approximately 5-10%, 2 g/day by 15-20%, and 4 g/day by 25-35% (Harris 2007, Am J Cardiol). The mechanism involves reduced hepatic VLDL-TG synthesis via PPAR-α activation, increased LPL-mediated TG clearance, and reduced apolipoprotein CIII (which inhibits TG hydrolysis). Prescription-strength icosapentaenoic acid (Vascepa/Lovaza) achieves 30-50% TG reduction in hypertriglyceridemia (>500 mg/dL), with corresponding reductions in chylomicron remnants and small dense LDL particles.
The ASCEND trial (Bowman 2018, NEJM, n=15,480 diabetics) found a non-significant 12% reduction in serious vascular events with 1 g/day omega-3 supplementation over 7.4 years—highlighting that dose matters. Meta-analyses including VITAL (Manson 2019, NEJM, n=25,871) found omega-3 at 1 g/day reduced total MI by 28% and fatal MI by 50% specifically in participants with low fish consumption at baseline, suggesting that baseline omega-3 status determines responsiveness. The Omega-3 Index (EPA+DHA as percent of total red blood cell fatty acids) provides the best individualized assessment: below 4% confers 10× higher sudden cardiac death risk vs. above 8% (Albert 2002, JAMA n=94 nested case-control).
For brain health, DHA comprises approximately 30-40% of total fatty acids in neuronal cell membranes, with concentration particularly high in synaptic terminals and photoreceptor outer segments. DHA deficiency impairs neuronal membrane fluidity, reduces synaptic vesicle exocytosis efficiency, and reduces BDNF signaling. The MIDAS trial (n=485, 900 mg DHA/day, 24 weeks) demonstrated significant improvement in episodic memory in healthy older adults. The OmegAD trial (Freund-Levi 2006, Arch Neurol, n=174) found omega-3 supplementation stabilized cognitive decline in mild Alzheimer’s disease (MMSE ≥15) over 6 months. Postpartum depression is associated with DHA depletion, with RCTs showing 200-400 mg DHA/day reduces PPD severity.
The Mediterranean Diet: Gold Standard Anti-Inflammatory Pattern
The Mediterranean dietary pattern—characterized by abundant extra-virgin olive oil, legumes, whole grains, vegetables, fruits, nuts, fish, and moderate red wine with limited red meat and refined carbohydrates—represents the most extensively studied anti-inflammatory dietary pattern with the strongest cardiovascular, metabolic, and cognitive outcome data.
The PREDIMED trial (Estruch 2013, NEJM, n=7,447) randomized high-cardiovascular-risk adults to Mediterranean diet supplemented with extra-virgin olive oil (EVOO, ~50 mL/day), Mediterranean diet supplemented with mixed nuts (30 g/day), or a low-fat control diet. The Mediterranean diet groups had 30% lower risk of major cardiovascular events (HR 0.70, 95% CI 0.54-0.92) over 4.8 years—a magnitude comparable to pharmacological intervention with statins. The trial was stopped early due to the clear magnitude of benefit. Secondary analyses found 40% lower T2DM incidence and 35% lower stroke risk in EVOO group specifically.
The PREDIMED-Plus trial (Salas-Salvadó 2020, NEJM, n=6,874) added caloric restriction and physical activity to Mediterranean diet in patients with metabolic syndrome, demonstrating superior body weight reduction and metabolic improvements vs. standard Mediterranean diet alone. The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay; Morris 2015, Alzheimer’s Dementia, n=923) found that highest adherence reduced Alzheimer’s risk by 53% and slowed cognitive aging by 7.5 years in a longitudinal cohort—with even moderate adherence producing 35% risk reduction.
Extra-virgin olive oil’s anti-inflammatory effects extend beyond monounsaturated fatty acid content. Oleocanthal—a phenolic compound in EVOO—inhibits COX-1 and COX-2 with potency similar to ibuprofen at comparable dietary doses (Beauchamp 2005, Nature). Oleuropein aglycone activates PPAR-γ and inhibits NF-κB. Total phenolic content varies dramatically by EVOO quality: cold-pressed, early harvest EVOO contains 300-500+ mg/kg polyphenols vs. refined olive oil at <20 mg/kg—functional medicine prescribes specific high-polyphenol EVOO by TPC certification rather than generic "olive oil."
Polyphenols: Mechanisms Beyond Antioxidation
Polyphenols—a class of over 8,000 plant-derived compounds including flavonoids, stilbenes, lignans, and phenolic acids—exert anti-inflammatory effects through mechanisms that go far beyond simple antioxidant activity. Polyphenols modulate signaling cascades at multiple levels: inhibiting NF-κB activation (quercetin, resveratrol, curcumin), activating Nrf2/KEAP1 pathway to upregulate endogenous antioxidant enzymes (sulforaphane, pterostilbene), activating SIRT1 (resveratrol), inhibiting NLRP3 inflammasome assembly (quercetin, luteolin), and modulating gut microbiome composition toward anti-inflammatory species.
Curcumin (from turmeric, Curcuma longa) inhibits NF-κB, COX-2, and 5-LOX while activating Nrf2 and PPAR-γ. The primary limitation is bioavailability: standard curcumin has <1% absorption due to rapid glucuronidation and sulfation. Piperine (black pepper, 20 mg) increases curcumin bioavailability by 2,000% via inhibition of glucuronidation (Shoba 1998). Phospholipid-complexed curcumin (Meriva), micellar preparations, and nanoparticulate forms achieve 29× higher bioavailability than standard curcumin powder. A meta-analysis of 21 RCTs (Sahebkar 2016, Phytomedicine) found high-bioavailability curcumin significantly reduced hsCRP (WMD -6.7 mg/L), ESR, and IL-6.
Resveratrol—a stilbene found in grape skins, red wine, and Japanese knotweed (Polygonum cuspidatum)—activates SIRT1 deacetylase (the longevity-associated sirtuin), which deacetylates and inhibits NF-κB p65 subunit, increases PGC-1α expression for mitochondrial biogenesis, and activates AMPK. Bioavailability issues similarly challenge resveratrol translation from preclinical data: standard trans-resveratrol is rapidly metabolized to resveratrol-3-O-glucuronide and resveratrol-3-O-sulfate, with <1% unchanged resveratrol reaching systemic circulation. Pterostilbene (the 3,5-dimethylated analog) achieves 80% oral bioavailability and crosses the blood-brain barrier more effectively. Clinical RCTs show modest but significant reductions in blood pressure (−7.6 mmHg systolic in Bhatt 2012 meta-analysis of 6 RCTs, n=247) and improvements in insulin sensitivity.
Quercetin—the most abundant dietary flavonol, found in onions, capers, berries, and green tea—inhibits NLRP3 inflammasome activation, reducing IL-1β and IL-18 production that drives gouty arthritis, atherosclerotic plaque rupture, and neuroinflammation. Quercetin also inhibits 5-LOX (reducing leukotriene synthesis) and COMT (prolonging catecholamine signaling). Clinical data: randomized trials in COPD (600 mg/day quercetin, 8 weeks) showed significant reduction in airway inflammation and DLCO improvement. The recently established senolytic activity of quercetin in combination with dasatinib (Kirkland 2019) suggests its role extends beyond acute anti-inflammation to elimination of senescent cells—addressing a root cause of aging-associated inflammation (“inflammaging”).
Sulforaphane and the Nrf2 Pathway
Sulforaphane—an isothiocyanate derived from glucoraphanin in cruciferous vegetables, particularly broccoli sprouts—is arguably the most potent dietary activator of the Nrf2/KEAP1 transcription factor pathway. Nrf2 regulates expression of over 200 cytoprotective genes including glutathione S-transferases (GSTs), NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), thioredoxin reductase, and ferritin—creating an endogenous antioxidant response that outlasts any individual antioxidant supplement.
Broccoli sprout consumption of 100 g (providing approximately 200 µmol sulforaphane, after myrosinase conversion from glucoraphanin) induces detoxification enzymes in the airway epithelium (Riedl 2009), reduces nasal mucosal NF-κB activity by 54% (Heber 2014), and in a randomized trial of 291 subjects in rural China (Egner 2014, Cancer Prevention Research), substantially increased excretion of aflatoxin-mercapturic acid and phenanthrene metabolites, demonstrating functional detoxification capacity. Fresh broccoli sprouts contain 10-100× more glucoraphanin than mature broccoli; cooking above 60°C inactivates myrosinase (the converting enzyme), so raw or lightly steamed sprouts are required, or myrosinase co-supplementation with sulforaphane glucosinolate supplements.
In the context of neuroinflammation, sulforaphane crosses the blood-brain barrier and activates Nrf2 in astrocytes and microglia, reducing neuroinflammation associated with traumatic brain injury, depression, and neurodegenerative diseases. A randomized double-blind placebo-controlled trial (Singh 2014, PLOS One, n=44) demonstrated significant improvement in social interaction, communication, and aberrant behaviors in young men with autism spectrum disorder receiving sulforaphane from broccoli sprout extract (dose equivalent to 9 g sprouts), with nearly complete reversal of gains at 18-week post-treatment follow-up, consistent with ongoing target engagement requirement.
Advanced Testing: Inflammatory Biomarkers and Omega-3 Status
Standard inflammatory assessment in conventional medicine relies primarily on high-sensitivity CRP (hsCRP), which is a downstream acute-phase reactant with relatively low specificity. Functional medicine employs an expanded inflammatory biomarker panel to characterize the source, chronicity, and target-organ involvement of inflammation:
hsCRP: Optimal below 0.5 mg/L (not merely “normal” below 3.0 mg/L). The JUPITER trial (Ridker 2008, NEJM, n=17,802) established that individuals with LDL-C below 130 mg/dL but hsCRP above 2.0 mg/L had dramatically higher cardiovascular risk and significant absolute benefit from rosuvastatin. Statin therapy reduces hsCRP independent of LDL reduction—the JUPITER finding catalyzed reclassification of inflammation as an independent cardiovascular risk factor equal to lipid abnormalities.
IL-6: The primary inducer of CRP synthesis in hepatocytes and a key driver of the metabolic syndrome—elevated in visceral adiposity independent of BMI. IL-6 predicts cardiovascular events 5-10 years before CRP elevation. The Mendelian randomization of IL-6 receptor polymorphisms (Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium, Lancet 2012) provided causal evidence that IL-6 signaling drives coronary heart disease—validating IL-6 as a therapeutic target beyond biomarker status.
TNF-α: The master pro-inflammatory cytokine activating NF-κB; elevated in metabolic syndrome, sleep apnea, and autoimmune disease. TNF-α directly causes insulin receptor serine phosphorylation—inhibiting insulin signaling and creating inflammation-driven insulin resistance. Biological agents targeting TNF-α (adalimumab, etanercept) reduce cardiovascular events in rheumatoid arthritis beyond their anti-inflammatory effects, consistent with TNF-α’s causal role in cardiovascular risk.
Omega-3 Index (HS-Omega-3 Index): EPA+DHA as percentage of total red blood cell fatty acids, the gold standard for tissue omega-3 status. Below 4% = high cardiovascular risk; 4-8% = intermediate; above 8% = low risk (target). The 10× gradient in sudden cardiac death risk between highest and lowest quartiles (Albert 2002) exceeds the risk gradient for most traditional risk factors. Baseline Omega-3 Index should be obtained before starting supplementation, with retest at 4 months (RBC lifespan)—response varies 2-5 fold between individuals based on FADS1/FADS2 polymorphisms that affect EPA-DHA metabolism.
Arachidonic acid:EPA ratio: Directly measures the eicosanoid balance at the membrane level. Target ratio below 3:1 (Western average is 15:1 or higher). This ratio predicts which patients will have the greatest anti-inflammatory response to omega-3 supplementation—those with high baseline AA:EPA ratios show the largest benefit.
Oxidized LDL (oxLDL): The biologically active form of LDL that triggers foam cell formation, plaque initiation, and NF-κB activation. oxLDL is elevated by smoking, hyperglycemia, and diets high in oxidized linoleic acid (from reheated vegetable oils). Polyphenols, vitamin E isomers, and CoQ10 reduce oxLDL independent of LDL-C levels.
Anti-Inflammatory Dietary Protocol: Clinical Application
The functional medicine anti-inflammatory nutrition protocol integrates the evidence from Mediterranean diet trials, omega-3 research, and phytonutrient biology into a clinically applicable framework:
Omega-3 fatty acids: Therapeutic doses of 2-4 g EPA+DHA daily from combined dietary sources (fatty fish: salmon, sardines, mackerel, herring 3-4×/week) and high-quality molecular distilled fish oil supplements (to remove PCBs, mercury, dioxins—verified by IFOS or NSF certification). For patients with cardiovascular disease or elevated TG, prescription-strength EPA (Vascepa/icosapentaenoic acid ethyl ester 4 g/day) achieves outcomes demonstrated in REDUCE-IT. Algae-derived DHA (Schizochytrium, Crypthecodinium) provides a vegan alternative particularly important during pregnancy (fetal brain development requires 300 mg DHA/day in third trimester). Monitor Omega-3 Index and AA:EPA ratio at baseline and 4 months.
Extra-virgin olive oil: 3-4 tablespoons (45-60 mL) daily as primary cooking fat and dressing. Select EVOO with Total Polyphenol Content (TPC) certification above 250 mg/kg—look for harvest date (within 18 months), early harvest (October-November), and pungency (oleocanthal-rich oil causes throat burn). Avoid light, refined, or “pure” olive oil which lack phenolic content. Use for low-heat cooking and finishing; avocado oil for high-heat cooking (higher smoke point, 270°C).
Phytonutrient density: The “30-plants” principle adapted for anti-inflammatory focus—targeting 30+ different plant foods weekly with emphasis on polyphenol-rich categories: dark berries (blueberries, bilberries, blackcurrants for anthocyanins), cruciferous vegetables (broccoli, kale, Brussels sprouts for sulforaphane), alliums (red onion, scallions, garlic for quercetin and allicin), herbs (rosemary for rosmarinic acid, turmeric for curcuminoids, green tea for EGCG). Color diversity approximates polyphenol diversity—functional medicine targets eating “across the rainbow” as a practical heuristic.
Elimination of pro-inflammatory foods: Trans fatty acids (partially hydrogenated oils—now largely eliminated by FDA ruling but still present in some processed foods), excessive omega-6 vegetable oils (soybean, corn, cottonseed, sunflower oil—replacing with EVOO, avocado oil, coconut oil for appropriate uses), ultra-processed foods (NOVA classification 4, associated with 62% increased all-cause mortality risk in NutriNet-Santé cohort, Srour 2019, BMJ, n=44,551), refined sugar and high-fructose corn syrup (activating NLRP3 inflammasome via uric acid), and excessive alcohol (beyond 1-2 servings/day increases IL-6 and TNF-α).
Advanced anti-inflammatory supplements: High-bioavailability curcumin (Meriva or micellar, 500-1,000 mg twice daily with meals); quercetin phytosome (500 mg twice daily); resveratrol or pterostilbene (100-200 mg/day); magnesium glycinate/malate (400-600 mg/day—deficiency in 45% of Americans drives NF-κB activation); vitamin D3 to maintain 60-80 ng/mL (profound anti-inflammatory effects via VDR nuclear receptor modulating 1,000+ genes); berberine (500 mg three times daily—equivalent anti-inflammatory potency to metformin via AMPK activation and NF-κB inhibition).
Autoimmune and Neuroinflammatory Applications
Chronic neuroinflammation—microglial activation, astrogliosis, and blood-brain barrier dysfunction—underlies depression, anxiety, cognitive decline, and neurodegenerative disease. The “inflammatory hypothesis of depression” (Dantzer 2008, Nature Reviews Neuroscience) positions neuroinflammation as a causal mechanism rather than epiphenomenon: individuals with inflammatory conditions have 2-3× higher depression prevalence, anti-TNF-α therapy reduces depression independent of disease control in rheumatoid arthritis, and surgical or infectious inflammation causes depressive behavioral changes via vagus-nerve-brain signaling of peripheral cytokines. EPA (not DHA) is the specific omega-3 with antidepressant efficacy—meta-analysis of 35 RCTs (Mocking 2016, Translational Psychiatry) found EPA-predominant formulations (>60% EPA) significantly reduced depressive symptoms with effect sizes comparable to antidepressants, while DHA-predominant formulations had no significant effect.
For rheumatoid arthritis, omega-3 supplementation (3-5 g EPA+DHA/day) reduces disease activity scores (DAS28), tender and swollen joint counts, morning stiffness duration, and NSAID requirements. The most rigorous meta-analysis (17 RCTs, Proudman 2015, Arthritis Care Research) confirmed significant benefit and introduced the “treat to target” omega-3 paradigm: achieve AA:EPA ratio below 3:1 as the laboratory target, adjusting dose accordingly. The GISSI-HF trial (2008, Lancet, n=6,975 heart failure patients) found omega-3 significantly reduced all-cause mortality (HR 0.91) and cardiovascular death/hospitalization (HR 0.92), establishing clinical benefit in an advanced disease population previously thought too ill to respond to nutritional intervention.
Lupus SLE provides an instructive example of dietary intervention in severe autoimmune disease: a pilot RCT (Duffy 2004, Annals of Rheumatic Diseases, n=60) found omega-3 3.5 g/day significantly reduced SLAM-R disease activity scores after 24 weeks. The anti-inflammatory diet reduces complement activation, anti-dsDNA antibody titers, and reduces flare frequency—though immunosuppressive medications remain essential for organ-threatening disease. Functional medicine positions nutrition as an adjunctive modulator, not a replacement for established therapies, while rigorously monitoring biomarker response.
GI and Microbiome Interactions with Inflammation
Intestinal permeability—the “leaky gut” phenomenon—allows lipopolysaccharide (LPS) from gram-negative bacteria to translocate into portal and systemic circulation, triggering TLR4-mediated NF-κB activation in liver, adipose tissue, and hypothalamus. This “metabolic endotoxemia” (Cani 2007, Diabetes, n=8) may initiate or perpetuate metabolic syndrome, visceral adiposity, and insulin resistance. A high-fat, low-fiber diet dramatically increases serum LPS within 4 weeks; Mediterranean diet and prebiotic fiber (inulin, pectin, arabinoxylan) reduce LPS by 38-40% in 12 weeks by promoting tight junction integrity and enriching protective species including Akkermansia muciniphila and Bifidobacterium longum.
Short-chain fatty acids (SCFAs)—particularly butyrate—produced by microbial fermentation of dietary fiber maintain intestinal barrier integrity by serving as the primary fuel for colonocytes, inducing tight junction protein expression (claudins, occludin, ZO-1), inhibiting NF-κB in intestinal epithelial cells via HDAC inhibition, and signaling via FFAR2/3 receptors to stimulate GLP-1 and PYY secretion (appetite regulation). A diet providing 30 g/day of fermentable fiber (not just total fiber)—from leeks, garlic, onions, asparagus, Jerusalem artichokes, green bananas, and cooked/cooled potatoes (resistant starch)—provides substrate for SCFA production. The Wastyk 2021 Cell trial (n=36) found fermented food consumption (6 servings/day yogurt, kefir, kimchi, kombucha) significantly increased microbiome diversity and reduced 19 inflammatory proteins—superior results compared to a high-fiber diet arm.
Frequently Asked Questions
How much omega-3 do I need for therapeutic anti-inflammatory effects?
Therapeutic anti-inflammatory effects require 2-4 g combined EPA+DHA daily—doses rarely achievable through diet alone (fatty fish 2-3×/week provides approximately 1-1.5 g). Most standard fish oil capsules contain 300-600 mg EPA+DHA per capsule, so 4-8 capsules daily may be needed. Concentrated omega-3 formulations (e.g., 800 mg EPA+DHA/capsule) reduce pill burden. The Omega-3 Index test (red blood cell EPA+DHA percentage) is the most accurate way to determine if your current intake is achieving tissue sufficiency—target above 8%. Response varies dramatically between individuals based on FADS1/FADS2 genetic polymorphisms that affect EPA-DHA synthesis and metabolism. Test baseline and retest at 4 months to optimize dose individually.
Is the Mediterranean diet actually proven to reduce inflammation, or is this just observational?
The Mediterranean diet has robust randomized controlled trial evidence, not merely observational associations. The PREDIMED trial (n=7,447, 4.8 years) demonstrated 30% cardiovascular event reduction in a pre-specified randomized comparison—stopped early by the data safety monitoring board due to magnitude of benefit. The PREDIMED-Plus (n=6,874) extended these findings. SMILES (Jacka 2017, BMC Medicine, n=67) demonstrated Mediterranean diet’s superiority over social support for treating major depression in a randomized controlled trial (32% remission vs. 8% control, NNT=4). Multiple mechanistic RCTs confirm that Mediterranean diet intervention reduces hsCRP, IL-6, oxLDL, and ICAM-1 within 8-12 weeks—demonstrating causality rather than mere correlation with inflammatory biomarker profiles.
Does curcumin actually work, and how do I choose a bioavailable form?
Standard curcumin powder has less than 1% bioavailability due to rapid conjugation in the gut wall and liver. The four evidence-based high-bioavailability forms are: (1) Meriva—phosphatidylcholine-curcumin complex (29× higher bioavailability than standard, with over 40 published clinical trials); (2) CurcuWin/UMAC-Core—micellar curcumin with 46× bioavailability; (3) BCM-95/Biocurcumax—curcuminoid + turmeric essential oil (6.93× bioavailability); and (4) Longvida—SLCP (solid lipid curcumin particle, optimized for blood-brain barrier penetration). Piperine (BioPerine, 5-20 mg) with standard curcumin increases bioavailability by 2,000% but also increases absorption of many medications (including blood thinners and immunosuppressants)—check drug interactions before combining. Effective clinical doses for inflammation: 500-1,000 mg twice daily of bioavailable form with meals containing fat.
What advanced testing should I get to assess my inflammatory status?
A comprehensive functional inflammation panel includes: hsCRP (target below 0.5 mg/L), homocysteine (target below 7 µmol/L—elevated homocysteine drives oxidative endothelial inflammation independently of lipids), fibrinogen (elevated in chronic inflammation and hypercoagulable states), Omega-3 Index via HS-Omega-3 Index test (target above 8%), arachidonic acid:EPA ratio (target below 3:1), oxidized LDL, ferritin (elevated in iron overload, metabolic syndrome, and chronic inflammation—optimal 50-100 ng/mL for men, 30-80 ng/mL for women), and, when autoimmune disease is suspected, anti-nuclear antibody (ANA), complement C3/C4, and specific autoantibody panels. For neuroinflammation evaluation, specialized labs (Cyrex Array 20) assess blood-brain barrier permeability markers including occludin/claudin antibodies and S100B.
Persistent chronic inflammation accelerates aging, increases all-cause mortality, and contributes to every major chronic disease category. The convergent evidence from multiple high-quality randomized controlled trials—PREDIMED, REDUCE-IT, JUPITER, and dozens of omega-3 and polyphenol trials—establishes that dietary modification at therapeutic intensity produces outcomes comparable to pharmacological intervention for inflammatory markers, cardiovascular risk, and metabolic health. At The Private Practice, Dr. Biernacki integrates comprehensive inflammatory biomarker assessment with precision dietary prescriptions, high-bioavailability supplement protocols, and regular biomarker monitoring to achieve measurable, documented reduction in inflammatory burden. This functional medicine approach addresses the root cause of chronic disease rather than suppressing downstream symptoms. To schedule an anti-inflammatory nutrition consultation, call (810) 206-1402.